Pfenex Inc (NYSEAMERICAN:PFNX) traded up 7.7% during mid-day trading on Thursday . The stock traded as high as $6.70 and last traded at $6.61, 418,353 shares changed hands during mid-day trading. An increase of 165% from the average session volume of 157,628 shares. The stock had previously closed at $6.14.
Several research analysts have issued reports on the company. Zacks Investment Research cut First Bancorp from a “buy” rating to a “hold” rating in a report on Thursday. William Blair reaffirmed a “buy” rating on shares of Pfenex in a report on Tuesday, April 2nd.
Pfenex (NYSEAMERICAN:PFNX) last announced its earnings results on Thursday, May 9th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.13. The firm had revenue of $10.36 million for the quarter, compared to analyst estimates of $5.63 million.
About Pfenex (NYSEAMERICAN:PFNX)
Pfenex Inc, a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study.
Featured Story: Inflation
Receive News & Ratings for Pfenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex and related companies with MarketBeat.com's FREE daily email newsletter.